These data suggest that direct modulation of PTEN protein expression in PIK3CA mutant ER+ BC models can modify the response to agents targeting the PI3K-AKT pathway, and that FOXM1 modulation can be a mechanistic biomarker informing on effective pathway inhibition. The gene discussed is PTEN; the disease is breast cancer.